Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CTOR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Denileukin Diftitox (E7777) FDA approved Aug 2024 · Lymphir |
Persistent or Recurrent Cutaneous T-Cell Lymphoma | Phase 3 · NCT01871727 | Completed |
| Combination - CITI-002 (high dose) | Hemorrhoids | Phase 2 · NCT05348200 | Completed |
Also used in these trials (approved or third-party drugs, not CTOR's own candidates): Hydrocortisone Acetate, Lidocaine Hydrochloride, Lidocaine, Halobetasol Propionate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CTOR holds $16.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
In addition, such statements could be affected by risks and uncertainties related to: ● our independent registered public accounting firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and…10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CTOR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 5%+ holder (13D) | 66,049,615 | 71.04% | 2026-05-15 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 9,394,202 | 10.10% | 2026-09-30 |
| Leonard L Mazur Chief Executive Officer, Director · +5.50M options |
Insider | 1,700,000 | 1.83% | 2026-11-09 |
| Myron Z Holubiak Secretary, Director · +1.60M options |
Insider | 950,000 | 1.02% | 2026-11-09 |
| Jaime Bartushak Chief Financial Officer · +2.20M options |
Insider | 825,000 | 0.89% | 2026-11-09 |
| Myron Czuczman Chief Medical Officer · +2.20M options |
Insider | 825,000 | 0.89% | 2026-11-09 |
| Joel David Mayersohn Director · +375,000 options |
Insider | 321,228 | 0.35% | 2026-11-12 |
| Eugene Myron Holuka Director · +400,000 options |
Insider | 300,000 | 0.32% | 2026-11-12 |
| Carol Webb Director · +400,000 options |
Insider | 300,000 | 0.32% | 2026-11-12 |
| Robert Joseph Smith Director · +250,000 options |
Insider | 300,000 | 0.32% | 2026-11-12 |
| Dennis M Mcgrath Director · +400,000 options |
Insider | 300,000 | 0.32% | 2026-11-12 |
| Suren G Dutia Director · +400,000 options |
Insider | 300,000 | 0.32% | 2026-11-12 |
Share count 92,981,204 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTOR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →